Detalles de la búsqueda
1.
Multi-institutional study of osimertinib dose-optimization in non-small cell lung cancer patients with EGFR activating mutation aged 70 years or older ('MONEY' trial).
Jpn J Clin Oncol;
2024 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38520037
2.
Prognostic significance of initial tumor shrinkage in patients with stage III non-small cell lung cancer treated with durvalumab following chemoradiotherapy.
Int J Clin Oncol;
29(2): 115-123, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38032455
3.
Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight.
Cancer Sci;
114(5): 2087-2097, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36704833
4.
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.
Cancer Sci;
114(8): 3330-3341, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37183528
5.
Observational study to predict the efficacy and optimal duration of nivolumab treatment in patients with previously treated advanced or recurrent non-small cell lung cancer.
Jpn J Clin Oncol;
53(2): 153-160, 2023 Jan 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36300307
6.
Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.
Cancer Sci;
113(1): 287-296, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34689382
7.
Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR).
Cancer Sci;
112(1): 388-396, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33185928
8.
Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913.
Invest New Drugs;
39(1): 202-209, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32803700
9.
A case series on the safety of immunotherapy with reduced blood testing frequency in lung cancer patients.
Int J Clin Oncol;
26(5): 851-857, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33656654
10.
High Serum OX40 and OX40 Ligand (OX40L) Levels Correlate with Reduced Survival in Patients with Advanced Lung Adenocarcinoma.
Oncology;
98(5): 303-310, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32097938
11.
A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101.
Int J Clin Oncol;
25(5): 867-875, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32060768
12.
Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.
Invest New Drugs;
37(6): 1207-1217, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30790152
13.
High Serum Soluble CD27 Level Correlates with Poor Performance Status and Reduced Survival in Patients with Advanced Lung Cancer.
Oncology;
97(6): 365-372, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31533124
14.
Radiographic Assessment of Objective Responses Using the ITMIG-Modified Criteria in Thymic Carcinoma.
Oncology;
97(5): 264-269, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31307031
15.
Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study.
Jpn J Clin Oncol;
49(7): 614-619, 2019 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30916304
16.
Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
Jpn J Clin Oncol;
49(8): 749-754, 2019 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31070750
17.
Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.
BMC Cancer;
18(1): 241, 2018 03 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29499653
18.
Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.
Invest New Drugs;
35(2): 217-226, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28138828
19.
Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
BMC Cancer;
17(1): 377, 2017 05 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-28549414
20.
Retrospective analysis of survival in patients with leptomeningeal carcinomatosis from lung adenocarcinoma treated with erlotinib and gefitinib.
Jpn J Clin Oncol;
47(4): 357-362, 2017 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28064206